A case of localized Prostate Cancer Marije Hamaker.

Slides:



Advertisements
Similar presentations
Progress Against Prostate Cancer. 1970–1979 Progress Against Prostate Cancer 1970–1979 Early 1970s: Radioactive ''seeds'' proven effective for prostate.
Advertisements

Implementing NICE guidance
A Case Study GP Masterclass Catherine Dale, RN, BSc Cancer Care
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
MODULE 5 1/33 Case 5: Sam. MODULE 5 Case 5: Sam 2/33 Patient History  Sam is a 66 year old retired painter & construction worker.  He is distressed.
British Association of Urological Surgeons Metastatic Prostate Cancer Guidelines.
MODULE 5 1/40 Case 3: Chuck. MODULE 5 Case 3: Chuck 2/40 Patient History  Chuck is a 66 year old retired chemical compounder  He is distressed by the.
Prostate Cancer Support Federation Charity Nº: We have no national screening programme for the most common cancer in men and the only test we.
2009. WHO IS A SURVIVOR? AN INDIVIDUAL IS A SURVIVOR FROM THE TIME OF THEIR DIAGNOSIS THROUGH THE BALANCE OF THEIR LIFE.
The Challenge of Prostate Cancer Genitourinary Cancer Center at M. D. Anderson PERSONALIZED MEDICINE.
MODULE 5 1/26 Case 6: Anthony. MODULE 5 Case 6: Anthony 2/26 Patient History  Anthony is a 55-year old lawyer.  He has been suffering from voiding complaints.
MODULE 5 1/23 Case 9: Pierre. MODULE 5 Case 9: Pierre 2/23 Patient History  Pierre is 65 years of age who has suffered with benign prostatic hyperplasia.
AM Report 9/11/09 Prostate Cancer Julia Rauch. Disease Burden ~220,000 men were diagnosed with prostate cancer in 2007 ~1/6 men will receive the disagnosis.
NEW OPTIONS IN PROSTATE CANCER TREATMENT Presented by Triangle Urology Associates, P.A.
Prostate Cancer Treatments By: Ishan Parikh. Symptoms Be on the look out for… “stop-and-go” flow of urine Sudden urges to urinate Frequent urination (esp.
Prostate Needle Biopsy: The Pitfalls and the Role of the Pathologist – Patient Track Prostate Cancer Symposium “Intriguing Cases / Emerging Strategies.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Bowel Cancer Alex Hill. Why screen for bowel cancer?  Bowel cancer causes deaths per yr  It may be detected at asymptomatic stage by simple, safe.
Akbar Ashrafi Surgical Students Society of Melbourne September 2010.
Medicare Annual Wellness Exam Presented by: Susan Duden, CPC. March 24, 2012.
Prostate Cancer Case Presentation Shireen Siddiqui.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Asim Pasha.  Common condition seen in older men  Risk factors  1-age:  Around 50% of 50-year-old men will have evidence of BPH and 30% will have symptoms.
Prostate Cancer Prostate cancer is the most common cancer detected in American men. The lifetime risk of a 50-year-old man for latent CaP is 40%; for.
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
A 74 year old man underwent open prostatectomy due to moderate to severe urinary symptoms unresponsive to medical therapy. Preoperative PSA was 4.1 Postoperatively.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
Some Current Issues in the Management of Prostate Cancer Suman Chatterjee MD.
Routine PSA: Evaluating the Evidence Sheldon Greenfield, MD Health Policy Research Institute University of California, Irvine October 23, 2012.
Prostate Pathology Emad Raddaoui, MD, FCAP, FASC.
EUROPA UOMO European Prostate Passport Recommendations from Berlin
CASE 1 65-year-old man No other diseases or previous surgeries July 2005: PSA 11.5 ng/ml; F/T: 9% After prostate biopsy revealing adenocarcinoma: RETROPUBIC.
Prostate Cancer Coalition of NC A statewide collaborative effort by concerned organizations and individuals to support awareness, early detection, and.
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
Prostate Pathology. Prostate weighs 20 grams in normal adult Retroperitoneal organ,encircling the neck of bladder and urethra Devoid of a distinct capsule.
© Copyright Annals of Internal Medicine, 2009 Ann Int Med. 164 (1): ITC1-1. In the Clinic Prostate Cancer.
Oncology 11 Localised Prostate Cancer VIVA
Prostate Cancer. What is the Prostate Gland What is the prostate Gland Size of a chestnut Just beneath the bladder Urethra runs through its middle Its.
HEAPHY 1 & 2 CASE RACE 1 – DIAG Yvonne CLARKE Sat 31 st Aug 2013 Session 3 / CR1-4 13:16 – 13:20 WELLINGTON ABSTRACT Following a woman’s pathway from her.
1 Prostate Cancer. 2 Prostate Gland Muscular Walnut-sized gland Makes seminal fluid Muscles contract to push semen through the urethra Located directly.
Understanding Prostate Myths
Trends in prostate cancer and its management in the South West Region, Hampshire and the Isle of Wight Christine Harling Julia Verne (SWPHO) Roy Maxwell.
Life after Prostate Cancer and its treatment Mr Sanjeev Pathak Consultant Urological Surgeon and Cancer Lead Doncaster and Bassetlaw NHS Trust 12 th March.
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.
Carcinoma of the prostate. INTRODUCTION Prostate cancer is the most common cancer diagnosed and is the second leading cause of cancer death in men in.
Prostate Cancer David Eedes 11 May Prostate Cancer Definition: Prostate cancer is a disease in which cells in the prostate gland become abnormal.
Prostate cancer and socio-economic deprivation When PCTs are ranked according to their income score using the Indices of Multiple Deprivation (IMD)* there.
Introduction to FM/GP as a specific medical discipline
Background Results Patients and methods Conclusions References
Bladder Cancer and Prostatic Cancer
J. Edson PontesM.D. Professor Urologic Oncology WSU/KCI
Prostate Cancer Dr .Gehan Mohamed.
PHEN Clinical Trials Rally
Your Symptoms Matter – Prostate Cancer
BREAST CANCER ONCOLOGY NAVIGATION SERVICE
Coordination (benign lesions)
Stomach cancer Also called gastric cancer is cancer arising from stomach tissue.it is uncontrolled cell growth of stomach layers lead to dysfunction of.
Dorset County Hospital Cancer of Unknown Primary (CUP) Service
Figure 3 Semantic model of the active surveillance (AS) timeline
Neuro Oncology Therapy Update
Prostate Cancer Screening- Update
Active Surveillance for Low Risk Prostate Cancer
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
Train-the-Trainer Cases
Train-the-Trainer Cases
Train-the-Trainer Cases
General strategies of Cancer Treatment and evaluation of Response
Standardised follow-up
Presentation transcript:

A case of localized Prostate Cancer Marije Hamaker

Disclosure Nothing to disclose

The patient 2014 Born on 1943, worked as police officer, living with wife, with 3 sons. 1,69 mt x 65 Kg Comorbidity: -Hypertension -Cerebrovascular event 1999, mild left emiparesis -Left carotid thromboarterectomy 2000 -Hypercholesterolemia Which is the life expectancy (71 years in 2014)? Whould you adivise for PSA screening in this patient? 3

Urological History The patient undergoes PSA testing in 2014= 3ng/mL (primary care physician's prescription? Wife-induced prescription?) PSA repeated in June 2015: 6.5 without urinary symptoms Urology consultation: Palpable induration in the left prostatic lobe Erectal dysfunction (no interest on the matter) Would you perform prostatic biopsies? 4

Prostatic Biopsy In Oct 2015 the patient undergoes prostatic biopsies and new PSA testing=45. -8 positive cores out of 12 samples -Adenocarcinoma of the prostate Gleason 4+5=9 (GRADE GROUP 5) -Perineural infiltration Would you proceed with radiological staging ? Which radiological exams? 5

Staging with PSA 45 ng/mL Abdomen CT scan: negative (apart from enlarged prostate) Bone scintigraphy: positive on left tibia and several joints …...previous bike fall Would you proceed with PET/CT scan? …...not performed 6

What would you do? Will a Gleason 9 prostate cancer influence life-expectancy of this patient? -Watchful waiting, no further exams until symptoms of metastatic disease or urinary obstruction -Active Surveillance not indicated. -Prostatectomy -Radiotherapy -LH-RH analogue 7

The First Treatment The patient starts LH-RH analogue without Radiotherapy consultation March 2016: PSA 1.3, mild hot-flashes The patient is advised by a friend to have a multidisciplinary consultation at our Institution Are LH-RH analogues safe in this patient? 8

“Multidisciplinary Prostate Clinic” March 2015: First visit at our Radioterapy/Oncology Multidisciplinary Clinic, accompanied by a son. 72 years, lives with wife, KPS=90 Mild gait alteration ABP 125/80 Cholesterol 199 mg/dL No bladder voiding symptoms 9

Full Geriatric Assessment ADL=6, IADL=3 MMSE: 19 BMI=22.7 GDS=8 3 medications: aspirin, ACE inhibitor, atorvastatine (in the past also antidepressant) Worried about “progression of tumor” and “approaching end of life” which will prevent him from seeing his grandchildren Vulnerable for IADL impairment and comorbidity level 10

SIOG GUIDELINES 11

Need for geriatric intervention? Long discussion with the patient concerning the prognosis and therapeutic options for his prostate cancer but ALSO for his current comorbidities and “oncogeriatric” issues SEDENTARY HABITS (walking, but no more bike) DEPRESSIVE ATTITUDES: psycho-oncological support + psychiatric consultation + increase family meetings CARDIOLOGICAL EVALUATION? 12

RADIOTHERAPY The patient has aggressive prostate cancer with high risk of micro-metastatic disease. Surgery is not taken into consideration for this patient (already excluded by urologist) He accepts the proposal of external radiotherapy (already on LH-RH analogues) in order to potentiate local control of disease MRI of the pelvis is requested in order to restage local extension of the tumor after hormonal therapy 13

DISCUSSION POINTS SCREENING for prostate cancer in the elderly: not recommended Hormonal therapy alone may be under-treatment in the elderly with high-risk prostat cancer Treatment choice is still based on first specialist seen by the patient & comorbidies Multidisciplinary Team Discussion should be applied in order for the patient to express his own wishes and concerns 14